Graham Capital Management L.P. Invests $1.78 Million in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Graham Capital Management L.P. bought a new stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLSGet Rating) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 35,030 shares of the company’s stock, valued at approximately $1,779,000.

Several other institutional investors and hedge funds also recently made changes to their positions in APLS. US Bancorp DE grew its holdings in Apellis Pharmaceuticals by 391.2% in the 1st quarter. US Bancorp DE now owns 1,110 shares of the company’s stock worth $56,000 after acquiring an additional 884 shares during the last quarter. Dupont Capital Management Corp purchased a new stake in shares of Apellis Pharmaceuticals in the 1st quarter worth about $161,000. Great West Life Assurance Co. Can lifted its position in shares of Apellis Pharmaceuticals by 15.5% in the 1st quarter. Great West Life Assurance Co. Can now owns 3,734 shares of the company’s stock worth $202,000 after purchasing an additional 500 shares during the period. Mackenzie Financial Corp purchased a new stake in shares of Apellis Pharmaceuticals in the 1st quarter worth about $206,000. Finally, LSP Investment Advisors LLC purchased a new stake in shares of Apellis Pharmaceuticals in the 4th quarter worth about $260,000. Institutional investors own 82.75% of the company’s stock.

Insider Activity at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, Director A. Sinclair Dunlop sold 30,000 shares of the firm’s stock in a transaction dated Thursday, August 11th. The stock was sold at an average price of $65.63, for a total value of $1,968,900.00. Following the transaction, the director now directly owns 255,679 shares of the company’s stock, valued at $16,780,212.77. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, SVP Mark Jeffrey Delong sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 17th. The shares were sold at an average price of $69.50, for a total transaction of $347,500.00. Following the completion of the sale, the senior vice president now directly owns 29,250 shares in the company, valued at $2,032,875. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director A. Sinclair Dunlop sold 30,000 shares of the company’s stock in a transaction that occurred on Thursday, August 11th. The shares were sold at an average price of $65.63, for a total transaction of $1,968,900.00. Following the sale, the director now directly owns 255,679 shares of the company’s stock, valued at $16,780,212.77. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 142,289 shares of company stock worth $8,071,218. 8.00% of the stock is owned by insiders.

Apellis Pharmaceuticals Stock Down 1.4 %

APLS opened at $67.57 on Friday. The stock has a market capitalization of $7.42 billion, a price-to-earnings ratio of -9.98 and a beta of 1.51. The firm has a 50 day moving average price of $57.92 and a 200-day moving average price of $50.13. Apellis Pharmaceuticals, Inc. has a twelve month low of $27.50 and a twelve month high of $70.00. The company has a quick ratio of 7.19, a current ratio of 7.57 and a debt-to-equity ratio of 0.57.

Apellis Pharmaceuticals (NASDAQ:APLSGet Rating) last announced its earnings results on Monday, August 8th. The company reported ($1.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.43) by ($0.03). Apellis Pharmaceuticals had a negative net margin of 660.59% and a negative return on equity of 272.25%. During the same quarter in the previous year, the business earned ($2.72) EPS. Equities research analysts forecast that Apellis Pharmaceuticals, Inc. will post -5.92 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Citigroup raised their target price on shares of Apellis Pharmaceuticals from $81.00 to $86.00 and gave the stock a “buy” rating in a research report on Wednesday, July 20th. Oppenheimer lifted their price target on shares of Apellis Pharmaceuticals from $68.00 to $78.00 and gave the company an “outperform” rating in a research report on Thursday, August 18th. HC Wainwright assumed coverage on shares of Apellis Pharmaceuticals in a research report on Tuesday, July 19th. They set a “buy” rating and a $75.00 price target for the company. The Goldman Sachs Group lifted their price target on shares of Apellis Pharmaceuticals from $91.00 to $102.00 and gave the company a “buy” rating in a research report on Tuesday, August 9th. Finally, Stifel Nicolaus lifted their price target on shares of Apellis Pharmaceuticals from $60.00 to $65.00 and gave the company a “buy” rating in a research report on Thursday. One analyst has rated the stock with a sell rating, two have issued a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Apellis Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $73.23.

Apellis Pharmaceuticals Company Profile

(Get Rating)

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases.

Read More

Want to see what other hedge funds are holding APLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Apellis Pharmaceuticals, Inc. (NASDAQ:APLSGet Rating).

Institutional Ownership by Quarter for Apellis Pharmaceuticals (NASDAQ:APLS)

Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.